Dr Reddy's Laboratories Ltd has announced that Glimy MP (Glimepiride+ Metformin+ Pioglitazone) has been launched nationwide in July 07 marking the entry of Dr Reddy's in the triple drug combination oral hypoglycaemic agents market.

Glimy MP is an extension of the existing products of Dr Reddy's, used in the management of type II diabetes. It is a one step approach to intensive glycolic control. Glimy MP is available in dosages of 1mg (Glimy MP1) and 2mg (Glimy MP2), in sizes of 10tabs /strip and 10strips/pack. The triple drug combination offers the range of options available for the doctor to address their needs in different situations in the management of type II diabetes.

The triple drug combination oral hypoglycaemic agents market is about Rs 62 crore in size and has grown by 176 per cent in the last one year (as per ORG MAT April'07).

Glimy MP is a new brand extension. Existing products of Dr Reddy's are GLIMY (Glimepiride 1,2,3,4 mg tabs), GLIMY-M (Glimepiride1 & 2 mg+ Metformin ER 500mg) and GLIMY-P (Glimepiride + Pioglitazone). Dr Reddy's is the first company to emphasize on HbA1C(Glycosylated Haemoglobin level) target as < 6.5 per cent. Glimy MPTM helps patients achieve the level of HbA1C < 6.5 per cent other brands of Dr Reddy's in this segment are Reclide and Reclimet.

Diabetes is a metabolic disease with three anomalies i.e. reduced insulin secretion, decreased insulin sensitivity and increased hepatic glucose production. Glimepiride works by increasing the insulin secretion (act on Pancreas), metformin acts by decreasing the hepatic glucose output (act on Liver), and pioglitazone acts by increasing the insulin sensitivity (act on peripheral tissues). Thus the triple combination addresses all the three anomalies in diabetes and thereby helps patients to achieve the target goal of HbA1C <6.5.